Aurobindo Pharma's US Joint Venture receives original generic approval for Ceftiofur Sodium Sterile Powder

Aurobindo Pharma Limited is pleased to announce that its US Joint Venture Cephazone Pharma LLC has received approval for its original Abbreviated New Animal Drug Application (ANADA) for Ceftiofur Sodium Sterile Powder from the US Food and Drug Administration Center for Veterinary Medicines.

Ceftiofur Sodium Sterile Powder is the generic equivalent of Pfizer Inc's NAXCEL® (Ceftiofur Sodium) Sterile Powder for injection. The product is approved for treatment of various bacterial infections in dogs, horses, cattle, swine, sheep, day-old chickens and day-old turkey poults.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

About Cephazone Pharma LLC. USA:

Cephazone pharma LLC USA is a 50:50 joint venture formed in 2001 between Aurobindo Pharma's wholly owned subsidiary APL Holdings Inc in association with Geravi Inc, a subsidiary of Medpharmex, USA to manufacture sterile and non-sterile cephalosporin products.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com